Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer by Toi, Masakazu et al.
RESEARCH ARTICLE Open Access
Differential survival following trastuzumab
treatment based on quantitative HER2 expression
and HER2 homodimers in a clinic-based cohort of
patients with metastatic breast cancer
Masakazu Toi
1*, Jeff Sperinde
2, Weidong Huang
3, Shigehira Saji
4, John Winslow
2, Xueguang Jin
2, Yuping Tan
2,
Shinji Ohno
5, Seigo Nakamura
6, Hiroji Iwata
7, Norikazu Masuda
8, Kenjiro Aogi
9, Satoshi Morita
10,
Christos Petropoulos
2, Michael Bates
3
Abstract
Background: We have recently described the correlation between quantitative measures of HER2 expression or
HER2 homodimers by the HERmark assay and objective response (RR), time-to progression (TTP), and overall
survival (OS) in an expanded access cohort of trastuzumab-treated HER2-positive patients with metastatic breast
cancer (MBC) who were stringently selected by fluorescence in situ hybridization (FISH). Multivariate analyses
suggested a continuum of HER2 expression that correlated with outcome following trastuzumab. Here we
investigate the relationship between HER2 expression or HER2 homodimers and OS in a clinic-based population of
patients with MBC selected primarily by IHC.
Methods: HERmark, a proximity-based assay designed to detect and quantitate protein expression and
dimerization in formalin-fixed paraffin-embedded (FFPE) tissues, was used to measure HER2 expression and HER2
homodimers in FFPE samples from patients with MBC. Assay results were correlated with OS using univariate
Kaplan-Meier, hazard function plots, and multivariate Cox regression analyses.
Results: Initial analyses revealed a parabolic relationship between continuous measures of HER2 expression and risk
of death, suggesting that the assumption of linearity for the HER2 expression measurements may be inappropriate
in subsequent multivariate analyses. Cox regression analyses using the categorized variable of HER2 expression
level demonstrated that higher HER2 levels predicted better survival outcomes following trastuzumab treatment in
the high HER2-expressing group.
Conclusions: These data suggest that the quantitative amount of HER2 expression measured by Hermark may be
a new useful marker to identify a more relevant target population for trastuzumab treatment in patients with MBC.
Background
Over-expression of HER2 has been linked to both
adverse prognosis and improved responsiveness to treat-
ment with trastuzumab (Herceptin, Genentech) in a
sub-population of metastatic breast cancers [1-5]. Tras-
tuzumab offers significant disease-free and overall survi-
val advantages in both the metastatic and adjuvant
settings in patients with HER2 over-expressing tumors
[ 6 - 1 1 ] .C u r r e n t l y ,t h es e l e c t ion of patients with breast
cancer for treatment with trastuzumab is based on the
measurement of HER2 receptor protein expression by
immunohistochemistry (IHC), or by the presence of
HER2 gene amplification as detected by FISH. Despite
the success of trastuzumab, recent data from NCCTG
9831, NSABP B-31, and CALGB 150002 have called
into question the accuracy of the current methods used
to identify those patients who are most likely to benefit
from treatment with trastuzumab [12-14]. New
approaches to the accurate quantitation of HER2
expression and HER2 dimerization in FFPE breast * Correspondence: toi@kuhp.kyoto-u.ac.jp
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responders more precisely.
We have previously reported that quantitative mea-
sures of HER2 expression or HER2 homodimers in FFPE
specimens from MBC patients enrolled in a trastuzumab
expanded access program identified sub-populations of
patients with different clinical outcomes, such that
patients whose tumors expressed higher levels of HER2
or HER2 homodimers lived longer [15]. Those patients
had been stringently selected for trastuzumab treatment
p r i m a r i l yb yF I S H( 9 0 % ) .H e r ew ed e s c r i b et h ec o r r e l a -
tion of quantitative measurements of HER2 expression
(H2T) or HER2 homodimers (H2D) with OS following
trastuzumab exposure in a cohort of patients with MBC
who were selected for treatment by IHC (88%) or FISH
(12%) in a routine clinic setting. Quantitative HER2 mea-
surements were made by the HERmark assay (Monogram
Biosciences) using FFPE breast tumor specimens. HER2
homodimers are defined as HER2:HER2 associations that
are sufficient to lead to HER2 phosphorylation and sub-
sequent activation of downstream signaling pathways.
These could include HER2:HER2 dimers or HER2 mono-
mers that are in close proximity (< 80 nm) as a result of
pathological over-expression.
Methods
The VeraTag technology
The VeraTag technology is a proximity-based method
designed to accurately and reproducibly quantitate pro-
tein expression and protein-protein complexes, includ-
ing cell surface-expressed protein dimers, in FFPE
specimens. The first assays developed for clinical testing
using the VeraTag platform measure HER2 protein
expression (H2T) and HER2 homodimer (H2D) levels
accurately and reproducibly, and are referred to as HER-
mark. These assays have undergone a formal validation
at Monogram Biosciences and are regulated by the Col-
lege of American Pathologists under the specifications
established by CLIA (Clinical Laboratory Improvement
Amendment) [16]. IHC (Herceptest, DAKO) and FISH
assays were performed according to standard protocols
at the local institutions where the patients were treated.
Description of the clinical cohort
This cohort is composed of 75 patients drawn from six
oncology clinics in Japan. Patients were included if they
had metastatic breast cancer, had been treated with at
least one chemotherapy regimen prior to receiving tras-
tuzumab either as single agent or in combination with
chemotherapy, and had FFPE specimens available for
testing by the HERmark assay. Assessments of HER2
over-expression by IHC or FISH were performed by the
pathologist at the local hospital. All clinical follow-up
was performed at the local hospital, and clinical
o u t c o m ed a t aw e r ed r a w nf r o mm e d i c a lc h a r tr e v i e w .
This study protocol was approved by the ethical com-
mittee of each institution and informed consent from
the patients was taken
Statistical methods
Measurements of H2T and H2D were tested for associa-
tion with OS, defined as the time from start of trastuzu-
mab treatment to cancer-associated death or the end of
the follow-up period. The log-transformed values of
HER2 expression and HER2 homodimers were used for
analyses. Deaths not attributed to breast cancer were
considered as censored at the time of death. One patient
was excluded from the analyses because she died merely
20 days after her first dose of trastuzumab, and the
duration of treatment was considered insufficient to
include the patient as “trastuzumab-treated.”
Univariate analyses were performed using the Kaplan
and Meier (KM) method, hazard function plots were
estimated using the life-table method, and multivariate
models were generated using Cox proportional hazards
regression analysis. Cox proportional hazards models
were fitted to examine the associations of H2T, H2D, or
their ratio H2T/H2D with outcome, with adjustment for
other potential prognostic factors. The adjustment fac-
tors included treatment group (trastuzumab-only or
trastuzumab plus chemotherapy), estrogen and proges-
terone receptor status, and a composite of them, hor-
mone receptor status, screening Herceptest score
performed at the treating hospital, Herceptest score
repeated at Monogram, Histoscore performed on repeat
IHC at Monogram, tumor stage, and presence of metas-
tases in the liver, lung, skin, bone, lymph nodes, brain,
chest wall, or other viscera. Metastatic sites occurring in
less than 10% of the total cohort were not considered as
individual variables. The st e p w i s ev a r i a b l es e l e c t i o n
method was used to select the “best” models.
Statistical analyses were performed at Yokohama City
University Medical Center using the statistical software
packages SAS and R.
Results and Discussion
The median duration of patient follow-up period was
18.2 months. The median duration of trastuzumab treat-
ment was 14.6 months. A description of the clinical
characteristics of the cohorti sp r o v i d e di nT a b l e1 .O f
the 75 patients with HER2 test +2 or +3 assessed at the
local hospitals, 25 had IHC 0 or +1 by the central
pathological review. Nine patients had advanced disease,
while 66 had recurrence. The number of pre-che-
motherapy before trastuzumab treatment was also
shown in Table 1. For the 66 patients with recurrence,
the number of pre-chemotherapy received after recur-
rence was analyzed.
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Page 2 of 10Table 1 Clinical characteristics of the cohort
Summary data
Characteristic Cohort
Geographic origin Japan
Type of cohot Clinic-based
Centralized HER2 assessment no
Centralized clinical data collection no
Length of follow-up (months) 3.4-63.3
Total Number of patients 75
Parameter Number of patients (%)
HER2 status by IHC 75 (100)
HER2 status by FISH 9(12.0)
Total Log10 HER2 expression ￿ Median Log10 HER2 expression ￿ Median
HER2 test at the local hospital
2+ 20 (26.7) 11 (28.9) 9 (24.3)
3+ 55 (73.3) 27 (71.1) 28 (75.7)
Centrally reviewed IHC
0 11 (14.7) 1 (2.6) 10 (27.0)
1+ 14 (18.7) 2 (5.3) 12 (32.4)
2+ 18 (24.0) 9 (23.7) 9 (24.3)
3+ 32 (42.7) 26 (68.4) 6 (16.2)
HER2 score on repeat testing
Mean (s.d.) 148 (101) 210 (71) 84 (87)
Min - Max 0 - 290 0 - 290 0 - 290
Hormone receptor status
ER+ PR+ 10 (13.3) 6 (15.8) 4 (10.8)
ER+ PR- 2 (2.7) 1 (2.6) 1 (2.7)
ER- PR+ 3 (4.0) 0 3 (8.1)
ER- PR- 60 (80.0) 31 (81.6) 29 (78.4)
ER unknown, PR- 0 0 0
ER unknown, PR unknown 0 0 0
Nodal status
Negative 21 (28.0) 14 (36.8) 7 (18.9)
1 to 3 positive nodes 23 (30.7) 9 (23.7) 14 (37.8)
4 to 10 positive nodes 8 (10.7) 4 (10.5) 4 (10.8)
> 10 positive nodes 17 (22.0) 7 (18.4) 10 (27.0)
Status missing 6 (8.0) 4 (10.5) 2 (5.4)
Tumor size
< = 2 cm 9 (12.0) 5 (13.2) 4 (10.8)
>2 cm & < = 5 cm 37 (49.3) 19 (50.0) 18 (48.7)
>5 cm 17 (22.7) 6 (15.8) 11 (29.7)
Missing 12 (16.0) 8 (21.1) 4 (10.8)
Prior adjuvant therapy
Adj HT 30 (40.0) 15 (39.5) 15 (40.5)
Adj CT 51 (68.0) 23 (60.5) 28 (75.7)
Adj HT only 5 (6.7) 2 (5.3) 3 (8.1)
Adj CT only 26 (34.7) 10 (26.3) 16 (43.2)
Adj HT & Adj CT 25 (33.3) 13 (34.2) 12 (32.4)
neither HT nor CT 19 (25.3) 13 (34.2) 6 (16.2)
Number of pre-chemotherapy before trastuzumab treatment*
0 41 (54.7) 18 (47.4) 23 (62.2)
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We have previously shown the relationship between
H E R m a r km e a s u r e so fH E R 2e x p r e s s i o na n dI H Cp e r -
formed under standard conditions by a single patholo-
gist in 170 FFPE breast tumors [16]. The results
demonstrated a general correlation between the two
assays, however the HERmark assay provided a more
quantitative assessment of HER2 expression distributed
over a 3-log dynamic range compared to the semi-
quantitative readout of IHC (0-3+ scale) (see Addi-
tional file 1: Figure S1). We attempted to make the
IHC measurement more quantitative by considering
the histo-score (H score), where staining intensity is
corrected for percent tumor involvement. The HER-
mark assay still demonstrated a greater ability to quan-
titate HER2 expression over a wider dynamic range.
In this cohort, we initially compared H2T to the
screening IHC calls provided by the treating hospitals.
The distribution of H2T measurements ranged over a
3-log dynamic range, and there was no significant dif-
ference between the H2T distributions of those sam-
ples scored as 2+ or 3+ by the screening IHC assays
(Figure 1a). We repeated the IHC assays on all speci-
mens. The repeat assays were performed centrally and
r e a db yas i n g l ep a t h o l o g i s t .A p p r o x i m a t e l yo n e - t h i r d
of the specimens were scored as 0 or 1+ upon repeat.
Comparison of the repeat IHC results with the HER2
expression levels by HERmark yielded a stair-step
correlation (Figure 1b) reminiscent of previous com-
parisons with centralized IHC results (see Additional
file 1, Figure S1).
Kaplan-Meier, hazard function plots, and multivariate Cox
analyses
As a whole, two-year survival rate of the cohort was
60.8% (95% C.I., 48.4 - 73.2%). In the univariate ana-
lyses, patients were classified into four subgroups
defined by the 25
th,5 0
th,a n d7 5
th percentiles for each
of the three variables, H2T, H2D, and their ratio H2D/
H2T, in order to examine the assumption of linearity
for the continuous variables used in the subsequent Cox
regression analysis. A significant difference in OS was
found between the four subgroups with respect to H2T
(Log rank test, p = 0.003; Figure 2), but not for the
o t h e r s( p=0 . 3 7 1a n dp=0 . 5 7 3 ) .T h e2 5
th,5 0
th,a n d
75
th percentiles for the log-transformed values of H2T
were 1.41, 1.80, and 2.25, respectively. The patients’
characteristics by H2T subgroup (< the median value of
H2T: n = 37 v.s. ￿ the median value of H2T: n = 37) is
summarized in Table 1. Higher proportion of patients
with greater H2T value than its median value had IHC
2+ or 3+ (p < 0.001) and higher HER2 score on repeat
testing (p < 0.001). No significant difference in OS was
found between the IHC subgroups (log-rank test: p =
0.610). Table 2 summarizes the other univariate analyses
for OS. Figure 3 shows the hazard function plots esti-
mated in the four H2T subgroups. The subgroups with
the 25% highest and lowest H2T values had substantially
lower risk of death than the middle two subgroups.
These univariate analyses revealed a parabolic relation-
ship between continuous measures of HER2 expression
and risk of death, suggesting that the assumption of lin-
earity for the HER2 expression measurements may be
Table 1: Clinical characteristics of the cohort (Continued)
1 15 (20.0) 9 (23.7) 6 (16.2)
2 or 3 7 (9.3) 3 (7.9) 4 (10.8)
N.A. 12 (16.0) 8 (21.1) 4 (10.8)
Tumor stage
Recurrence 66 (88.0) 32 (84.2) 34 (91.9)
Advanced 9 (12.0) 6 (15.8) 3 (8.1)
Number of met sites
1 or 2 49 (65.3) 25 (65.8) 24 (64.9)
3 or 4 25 (33.3) 12 (31.6) 13 (35.1)
unknown 1 (1.3) 1 (2.6) 0
Brain mets
yes 7 (9.3) 5 (13.2) 2 (5.4)
no 68 (90.7) 33 (86.8) 35 (94.6)
Treatment
Herceptin + chemo 63 (84.0) 31 (81.6) 32 (86.5)
Herceptin only 12 (16.0) 7 (13.5) 5 (18.4)
* For the 66 patients with recurrence, the number of pre-chemotherapy received after recurrence was analyzed.
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shown in Table 3, this parabolic relationship was also
confirmed by the Cox regression analysis using the cate-
gorized variable of H2T (compared with the reference
subgroup having higher 50%-75% H2T, HR of the 25%
highest = 0.25, p = 0.019, 95%CI: 0.08-0.77; HR of the
25%-50% = 0.79, p = 0.610, 95%CI: 0.32-1.97; HR of the
25% lowest = 0.12, p = 0.004, 95%CI: 0.03-0.51), which
also shows that hormone receptor status (HR = 0.18, p
= 0.014, 95%CI: 0.04-0.71) and brain metastases (HR =
0.07, p < 0.001, 95%CI: 0.02-0.24) were significant prog-
nostic factors. Thus, the best multivariate model con-
tained three variables, H2T, progesterone receptor
status, and brain metastases.
Dividing the cohort into high HER2-expressing (≥ the
median value of H2T) and low HER2-expressing (< the
Figure 1 Relationship between ICH results and HER mark measures of HER2. (a) Screening IHC results correlated with HER2 expression. (b)
Repeat IHC results, all patients (compare to Figure S1).
Figure 2 Kaplan-Meier curve of OS by HER2 expression subgroup.
Toi et al. BMC Cancer 2010, 10:56
http://www.biomedcentral.com/1471-2407/10/56
Page 5 of 10median value of H2T) sub-groups and using the Cox
regression analysis with the continuous H2T value in
each of the two subgroups, we found that those patients
with higher values for HER2 expression live longer than
those with lower values for H2T in the high HER2-
expressing group (HR = 0.06, p = 0.010, 95%CI: 0.01-
0.51) (Table 4). In contrast, in the low HER2-expressing
group, the opposite trend (those with lower H2T values
are favored) was observed (HR = 16.0, p = 0.017, 95%CI:
1.64-155.9). These data suggest that there are two sub-
populations of patients in this cohort that behave differ-
ently with respect to HER2 expression and OS.
Trastuzumab is a remarkably effective drug for
patients with breast cancer who over-express HER2, or
have evidence of HER2 gene amplification. However,
not all patients with MBC respond to trastuzumab, per-
haps because not all patients who receive the drug are
truly over-expressing HER2, or perhaps because some
proportion of those that do over-express HER2 also sig-
nal through other pathways that are not antagonized
Table 3 Cox regression for survival time using the stepwise variable selection method.
Variable Category Hazard ratio 95% C.I. P-value
Log10HER2 expression (1) 75 percentile~/50~ 75 percentile 0.25 0.08 0.77 0.019
Log10HER2 expression (2) 25~ 50 percentile/50~ 75 percentile 0.79 0.32 1.97 0.610
Log10HER2 expression (3) ~ 25 percentile/50~ 75 percentile 0.12 0.03 0.51 0.004
Hormone receptor status +/- 0.18 0.04 0.71 0.014
Brain mets No/Yes 0.07 0.02 0.24 <.0001
Table 2 Univariate analysis for overall survival time.
Variable Category Hazard ratio 95% C.I. P-value
Treatment group trastuzumab/trastzumab+chemo 1.24 0.43 3.56 0.693
ER +/- 0.81 0.28 2.33 0.694
PR +/- 0.45 0.14 1.49 0.190
Hormone receptor +/- 0.53 0.19 1.54 0.244
Tumor stage Recurrence/advanced 3.30 0.45 24.4 0.242
No. of metastatic sites 1/2/3/4 0.54 0.37 0.79 0.002
Liver mets No/Yes 0.74 0.34 1.59 0.435
Lung mets No/Yes 0.83 0.40 1.72 0.615
Bone mets No/Yes 0.42 0.20 0.88 0.021
Lymph node mets No/Yes 1.02 0.49 2.14 0.959
Brain mets No/Yes 0.18 0.07 0.46 <.0001
Figure 3 Hazard function plots with six-month interval by HER2 expression subgroup.
Toi et al. BMC Cancer 2010, 10:56
http://www.biomedcentral.com/1471-2407/10/56
Page 6 of 10effectively by trastuzumab. Such patients may be
expected to experience fleeting responses when treated
with trastuzumab, or even to show no evidence of clini-
cal response at all. As the ability to accurately assess
such escape pathways gradually evolves, we should be
able to identify the mechanisms of resistance to trastu-
zumab, so that effective strategies for combination ther-
apy can be developed and tested in prospective clinical
trials. That process will take time, but perhaps a first
step could be to improve our ability to accurately quan-
titate HER2 protein expression and try to gain a better
understanding of how differences in expression levels
among individual breast tumors affect the natural his-
tory of HER2-positive breast cancer and, more impor-
tantly, response to HER2-targeted agents like
trastuzumab.
Recently presented data at the 2007 ASCO annual
meeting have raised questions about the accuracy of
current testing methods [12-14]. In particular, a re-
analysis of the central testing data from the NSABP B-
31 trial demonstrated that nearly 10% of the trastuzu-
mab-treated population in the trial were IHC < 3+,
FISH-negative on repeat testing, but benefited from
trastuzumab therapy just as the IHC 3+ and FISH-
positive groups did [14]. Perhaps this observation
reflects fundamental differences between the pathophy-
siology of breast cancer in the adjuvant setting com-
pared with the metastatic setting, or perhaps we need
better tests for HER2. Whatever the case, there
appears to be a genuine need to re-examine the issue
of patient selection for trastuzumab, with an eye
toward new technologies and new approaches that
have the potential not only to improve current stan-
dards, but also to begin identifying alternative signaling
complexes that can be targeted by combination therapy
regimens including trastuzumab.
In this study, we describe the relationship between
quantitative measures of HER2 expression or HER2
homodimers and overall survival in a cohort of patients
with MBC who were treated with trastuzumab. The
assay system used to make these measurements is CLIA
validated for accuracy and reproducibility, and by virtue
of its ability to quantitate proteins and protein dimers,
provides a more granular view of the HER2 landscape
than either IHC or FISH [16]. The assay has previously
been correlated with clinical outcomes following trastu-
zumab therapy in a cohort of MBC patients who were
very carefully selected for treatment using FISH at the
Jules Bordet Institute in Belgium [15].
The current study represents the second clinical
experience with the HERmark assay, involving a group
of patients who were selected for trastuzumab treatment
primarily by IHC (88%) performed in the course of rou-
tine clinical care. The initial KM analyses and hazard
function plots of the entire cohort suggested that two
distinct populations were present, and the observed rela-
tionships between HER2 expression and OS for the two
sub-groups were going in opposite directions. Using a
cutoff of the median value of log10 HER2 expression =
1.80, we then re-analyzed the patient sub-group that
had HER2 expression values greater than the cutoff to
see whether this sub-population showed any evidence
that higher levels of HER2 expression yielded longer OS
on trastuzumab. Data from the Bordet cohort described
previously had shown such an association, and we
wanted to see if we could confirm this relationship in
the current study. Because the Bordet cohort was so
stringently selected for HER2 over-expression or gene
amplification, patients with low HER2-expression, such
as those that represented approximately one-third of the
current cohort, may have been excluded. Given the dif-
ferences in the methodology used to select patients in
the two cohorts (90% FISH in Bordet, 88% IHC in the
current study), as well as the stringency applied
(expanded access cohort with mandatory central confir-
mation of HER2 status in Bordet, routine clinical care in
the current study), it is perhaps not so surprising that
we might observe this difference. These data appear to
confirm the relationships that were seen in the Bordet
cohort and also suggest that, within a population of
patients that are identified as HER2-positive by the com-
monly used methods currently available to clinical
oncologists, precise quantitation of HER2 expression
can define multiple sub-populations of patients that
experience different clinical outcomes in response to
trastuzumab treatment.
Table 4 Cox regression analyses in two subgroups divided by the median HER2 expression value.
Cohort subset> Variable Hazard ratio 95%C.I. P-value
Log10HER2 expression ￿ 1.799* Log10 HER2 expression 0.06 0.01 - 0.51 0.010
(n = 37) Hormone receptor status 0.39 0.05 - 2.86 0.354
Brain mets 0.14 0.02 - 0.87 0.034
Log10HER2 expression < 1.799* Log10 HER2 expression 16.0 1.64 - 155.9 0.017
(n = 37) Hormone receptor status 0.20 0.03 - 1.57 0.125
Brain mets 0.04 0.01 - 0.28 0.001
* Median (50 percentile) value of Log10HER2 expression measurements
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according to the degree of HER2 protein expression that
their tumors exhibit, and that quantitative expression
levels matter clinically. It is important to note that these
data do not address the question of whether some
patients treated with trastuzumab may not benefit clini-
cally. Because we tested only patients who were treated
with trastuzumab, the finding that some did not benefit
as much as others does not equate to some did not ben-
efit at all. Prospective studies or retrospective analyses of
prospectively designed clinical trials where HER2-posi-
tive patients were randomized to receive trastuzumab or
not will need to be tested in order to answer that ques-
tion. Nonetheless, data from the current study demon-
strate that trastuzumab-treated patients with low HER2
expression levels appear to behave differently with
respect to OS than those with high HER2 expression
levels. Whether this subset of patients behaves differ-
ently because they exhibit normal rather than elevated
but low levels of HER2 is a matter for future study. In
addition, we should have carried out the analyses to
examine the relationship between HER2 expression
levels and OS in patients with IHC 2+ or 3+. We could
not obtain statistically reliable results, however, because
the number of patients included in the subgroup was
small (n = 50) and, in particular, the number of patients
with brain metastases was only 5. This is also a matter
for future study.
What do these data imply about the impact of trastu-
zumab on HER2-positive tumors that express different
levels of the target? Previous data have shown that the
amount of HER2 protein expressed correlates with dis-
ease progression in MBC patients not treated with tras-
tuzumab [3]. Data from the current study are restricted
to patients that have been treated with trastuzumab, but
nonetheless support the general conclusion that the
amount of HER2 expression matters clinically. One
potential explanation for such a finding is that the
amount of HER2 expression is a marker for the degree
of HER2 dependency that exists in the tumor. Tumors
that massively over-express HER2 may be “addicted” to
signaling through HER2, potentially explaining their
association with rapid progression in the absence of
trastuzumab as well as enhanced susceptibility to antag-
onism by trastuzumab. Tumors which express lower
l e v e l so fH E R 2m a yb el e s sv u l n e r a b l et ot r a s t u z u m a b
because they are less dependent on HER2 alone, but
rather derive at least some of their proliferative drive
from protein-protein associations (HER1:HER2 or
HER2:HER3 heterodimers) or variants (p95/HER2) that
a r en o ta ss u s c e p t i b l et oa n t a g o n i s mb yt r a s t u z u m a b
[17-23]. Other explanations involving mutations in
downstream components (PTEN) that affect PI3-kinase
signaling activity as well as involvement of alternative
signaling pathways (eg. IGF-1R) are equally plausible
[24,25]. Alternatively, the association between higher
levels of HER2 expression and better outcomes on tras-
tuzumab may reflect enhanced targeting of HER2 over-
expressing cells by immune mechanisms triggered by
trastuzumab binding, like antibody dependent cellular
cytotoxicity (ADCC). Perhaps tumors at the lowest end
of the HER2-expression distribution, that appear to have
favored outcomes on trastuzumab, are simply expressing
normal levels of HER2, and thus have a fundamentally
different prognosis than their counterparts expressing
significantly higher levels of HER2. These questions, as
well as the general finding that, among tumors already
classified as HER2 over-expressing or gene-amplified by
standard assays, precise assessments of HER2 expression
levels correlate with clinical outcomes following trastu-
zumab treatment, demand further scrutiny in larger,
well-controlled trials of patients with metastatic breast
cancer.
Although the technology enabling quantitative assess-
ments of potential escape pathways for trastuzumab is
still evolving, the opportunity to begin to sub-divide
p o p u l a t i o n so fp a t i e n t si n t ot h e i rc o n s t i t u e n tg r o u p s
based on precise measurements of HER2 and its family
members holds tremendous promise at a time when
numerous targeted drugs are becoming available for
inclusion in combination therapy regimens for patients
with breast cancer. It is our hope that observations
derived from the current study represent an early step
in that direction.
Conclusion
It is concluded that the quantitive HER2 measurement
by Hermark assay may be useful for identifying a more
relevant target population to trastuzumab treatment in
patients with MBC. It is warranted to study the signifi-
cance of the quantitive HER2 measurement in the adju-
vant situation with anti-HER2 therapy for primary
breast cancer patients.
Additional file 1: Figure S1. Correlation of HER2 expression Vera
Tag and IHC in 170 breast tumors (FFPE). The correlation between
the Vera Tag measure of HER2 expression and IHC in 170 FFPE breast
tumor specimens. This is a reproduction of figure 6a from Shi, et al.
(footnote 2) provided here for convenience.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
56-S1.DOC]
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